title: The practice of pre-marketing safety assessment in drug development.
abstract: The last 15 years have seen a substantial increase in efforts devoted to safety assessment by statisticians in the pharmaceutical industry. While some of these efforts were driven by regulations and public demand for safer products, much of the motivation came from the realization that there is a strong need for a systematic approach to safety planning, evaluation, and reporting at the program level throughout the drug development life cycle. An efficient process can help us identify safety signals early and afford us the opportunity to develop effective risk minimization plan early in the development cycle. This awareness has led many pharmaceutical sponsors to set up internal systems and structures to effectively conduct safety assessment at all levels (patient, study, and program). In addition to process, tools have emerged that are designed to enhance data review and pattern recognition. In this paper, we describe advancements in the practice of safety assessment during the premarketing phase of drug development. In particular, we share examples of safety assessment practice at our respective companies, some of which are based on recommendations from industry-initiated working groups on best practice in recent years.
authors: Statistical Research and Consulting Center, Pfizer Inc, Kalamazoo, Michigan 49009, USA. christy.j.chuang-stein@pfizer.com
authors: Christy
authors: C
authors: Chuang-Stein
authors: H Amy
authors: HA
authors: Xia
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics / Q000592:standards; D055808:Drug Discovery / Q000191:economics / Q000592:standards*; D004345:Drug Industry / Q000191:economics / Q000592:standards*; D006801:Humans; D040541:Marketing; D061214:Patient Safety / Q000191:economics / Q000592:standards*; D004364:Pharmaceutical Preparations / Q000191:economics / Q000592:standards*
chemical_list: D004364:Pharmaceutical Preparations